Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
China
Biotech
Ascletis prepares for China regulators after acne pill ph. 3 win
The Chinese biotech claimed the Sagimet Biosciences-sourced drug can hold its own against Seysara and doxycycline.
James Waldron
Jun 4, 2025 5:08am
BioAge inks option agreement for Chinese biotech's obesity asset
Jun 3, 2025 2:06pm
Astellas aims for CLDN18.2 gold with $1.34B licensing deal
May 29, 2025 7:30pm
Juri inks $210M T-cell engager deal with China biotech
May 27, 2025 6:00am
PacBio expands reach in China with clinical distribution deal
May 22, 2025 12:00pm
CRISPR Tx, Sirius pen collab with a focus on thrombotic disease
May 20, 2025 3:59am
